A COMPARATIVE RESEARCH TO ASCERTAIN VIROLOGIC REACTION IN CHRONIC HEPATITIS C VIRUS (HCV) PATIENTS BY TWO DIFFERENT TREATMENT OPTIONS

Objective: This study was designed to ascertain the virologic reactions in patients of chronic hepatitis C, cured by means of sofosbuvir and daclatasvir versus sofosbuvir and ribavirin. Methodology: It was a probable comparative research study which was administered in Allied Hospital, Faisalabad from February to October 2017. With either gender, chronic hepatitis C virus detected patients with age ranges from 18 to 60 years having detectable HCV RNA through PCR were select for study. Based on treatment, patients were divided into 2 categories; group A patients were handled with sofosbuvir + daclatasvir and group B with sofosbuvir + ribazole. For HCV RNA Quantitative, PCR had been carrying out to measure the viral RVR (at 4th week), EVR (at 12th week), ETR (at 24th week) and SVR after completion of 24 weeks treatment. The patients who failed to comply with treatment or having any impediment to investigations that caused to treatment cancellation were excluded from the study. Results: Total 107 patients with average age of 36.46+11.34 years were select for study and majority (58.9%) of them were female. 19.6% patients treated with sofosbuvir + ribazole and remaining 80.4% with sofosbuvir + daclatasvir. In group A (sofosbuvir + daclatasvir) RVR, EVR, ETR & SVR* were significantly more with respect to group B (sofosbuvir + ribazole). In group B, 18 out of 21 patients achieved ETR. Post-treatment completion in both groups, no substantial variance founded in the viral load mean p-value 0.628. Conclusion: Both treatments proved to have good effectiveness, however, sofosbuvir + declacavir treatment attained more important RVR, EVR, ETR and SVR with respect to sofosbuvir + ribazole. Keywords: RVR: (Rapid Viral load Response), EVR: (Early Viral load Response), ETR: (End Treatment Response) and SVR: (Sustained Viral Response